Skip to main content
BioMedical Engineering OnLine logoLink to BioMedical Engineering OnLine
. 2010 Mar 14;9:17. doi: 10.1186/1475-925X-9-17

A portable automatic cough analyser in the ambulatory assessment of cough

Malgorzata Krajnik 1, Iwona Damps-Konstanska 2,, Lucyna Gorska 2, Ewa Jassem 2
PMCID: PMC2848140  PMID: 20226089

Abstract

Background

Cough is one of the main symptoms of advanced lung disease. However, the efficacy of currently available treatment remains unsatisfactory. Research into the new antitussives requires an objective assessment of cough.

Methods

The aim of the study was to test the feasibility of a new automatic portable cough analyser and assess the correlation between subjective and objective evaluations of cough in 13 patients with chronic cough. The patients' individual histories, a cough symptom score and a numeric cough scale (1-10) were used as a subjective evaluation of cough and a computerized audio-timed recorder was used to measure the frequency of coughing.

Results

The pre-clinical validation has shown that an automated cough analyser is an accurate and reliable tool for the ambulatory assessment of chronic cough. In the clinical part of the experiment for the daytime, subjective cough scoring correlated with the number of all cough incidents recorded by the cough analyser (r = 0.63; p = 0.022) and the number of cough incidents per hour (r = 0.60; p = 0.03). However, there was no relation between cough score and the time spent coughing per hour (r = 0.48; p = 0.1). As assessed for the night-time period, no correlation was found between subjective cough scoring and the number of incidents per hour (r = 0.29; p = 0.34) or time spent coughing (r = 0.26; p = 0.4).

Conclusion

An automated cough analyser seems to be a feasible tool for the ambulatory monitoring of cough. There is a moderate correlation between subjective and objective assessments of cough during the daytime, whereas the discrepancy in the evaluation of night-time coughing might suggest that subjective analysis is unreliable.

Background

Cough is one of the main symptoms of advanced lung disease. However, the efficacy of currently available treatment remains unsatisfactory. Growing knowledge of the pathophysiology of cough has resulted in the implementation of new therapeutic options and research on future potential treatment modalities [1-3]. Research into the efficacy of antitussives would, however, require the objective assessment of cough. Until now the evaluation of the frequency and severity of cough has been based mainly on patients' subjective reporting. According to the guidelines of the European Respiratory Society (ERS) and the American College of Chest Physicians (ACCP), treatment efficacy for chronic respiratory diseases should be assessed using an objective method of cough monitoring [4,5]. This very recent recommendation reflects observations from preliminary studies suggesting a poor and variable relationship between different subjective and objective measures of cough [6-11]. Despite great progress in the objective evaluation of cough, the introduction of equipment which would be useful in everyday clinical practice remains a challenge. Such portable, low-weight systems should be simple in their use and application, acceptable to patients and reliable.

In this study we first tested the feasibility of a new portable automatic cough analyser (CA) which could be applied to 24-hour monitoring in an ambulatory setting (Figure 1). We then used this method to determine the relation between subjective cough scores and objective monitoring by a CA. The aim of the clinical part of the study was to assess the relation between patients' evaluations and an objective measurement of cough frequency and time spent coughing.

Figure 1.

Figure 1

Cough analyser. The cough analyser registered all events continuously and automatically. Patients were handling a device which allowed them to mark certain important incidents, for example incidental dyspnoea.

Methods

Patients

Sixteen patients who had been treated at the Department of Pneumonology and Allergology at the Medical University of Gdansk, Poland, were included in the study (Table 1).

Table 1.

Characteristics of the patients with respiratory diseases included in the study.

Nr Gender
F/M
Age
(years)
Diagnosis Dyspnoea (Borg scale) Spirometry (% of predicted)

FEV1 FVC IN FVC EX FEV1/FVC
1 F 55 Asthma 3 106 104 108 83
2 F 43 Asthma 3 65 76 81 69
3 F 19 Asthma - 105 109 110 83
4 M 34 Asthma 0 76 87 88 71
5 F 36 Asthma 4 101 102 109 79
6 F 58 Asthma 2 37 48 51 61
7 M 48 BHR 2 99 107 110 72
8 F 55 Asthma 5 125 137 143 74
9 F 56 Asthma 5 58 65 72 68
10 F 46 Asthma - 104 104 110 81
11 F 56 Asthma - 106 108 111 81
12 M 53 Asthma 1 96 121 122 62
13 F 48 BHR 2 107 122 127 72
14 F 31 BHR 1 118 122 126 81
15 M 51 Asthma 0 88 113 113 62
16 M 53 BHR 0.5 147 158 155 76

Patients 3, 10 and 11 did not complete the Borg scale; BHR - bronchial hyper-reactivity

The inclusion criteria were as follows: chronic cough defined according to the ERS [4], being over the age of 18, and giving written informed consent.

The exclusion criterion was asthma exacerbation. The study was approved by the Local Research Ethics Committee in Gdansk and patients' individual histories, a cough symptom score and a numeric cough scale (1-10) were used for a subjective evaluation of cough. Portable cough recording was commenced following lung function assessment by spirometry. In the case of ambulatory patients, these were allowed to go home and encouraged to wear the cough-recording device for 24 hours. Moreover, they were asked to self-report their cough during the day and night.

Cough analyser

The cough analyser (CA) designed for the purpose of the study (MES, Kraków, Poland) was supplied with batteries (2 × AAA 2.4 V) and worn by patients in a special pouch around the thorax (Figure 1). A microphone with a reading frequency of 8-1200 Hz was attached to the pouch and localized in the lower part of the sternum, approximately 30 cm from the mouth. Signals from a microphone detector were continuously registered on a flash memory. After completing the analysis, data were transferred from the recorder to a personal computer and read automatically by the software (MES, Kraków, Poland), allowing for the analysis of particular parameters.

The CA was able to measure acoustic vibrations continuously and the signals being transferred to a recording of sound amplitude. The hardware for the CA allows for a 0.1-second resolution time in registering signals with a cut-off value of 20 dB, whereas the frequency range is 8-1200 Hz.

Pre-clinical part of the experiment: validation of the MES CA

The process of the MES CA validation consisted of three steps.

First - 6 healthy individuals voluntarily produced cough. A comparison of the agreement of manual counting by software using the MES Cough Analyser against counting by the hearing of cough incidents in real time was checked. The counting error (ECh-m) was assessed according to the following mathematical formula:

graphic file with name 1475-925X-9-17-i1.gif

Nh - number of incidents counted from hearing in real time

Nm - number of incidents counted manually by the software

As Nh = 1069 and Nm = 1065, the ECh-m was equal to 0.37%.

Discrimination afforded by the manual counting of recordings with software for the MES CA was observed to be consistent with that achieved by counting in real time. Thus, the manual counting of the recordings was assessed as reliable and used in the next steps as the method of reference for automatic counting.

Second - the calibration of the cough analyser.

Six healthy volunteers coughed in their normal office environments at work (where external noise such as talking was present) (Table 2). The counting error (ECa-m) was evaluated for different parameters of automatic analysis, such as time (0.1 s or 1 s) and amplitude of discrimination (5%, 10%, 20% or 40%).

Table 2.

The calibration of the cough analyser

Nr Nh Nm Automatic counting by the cough analyser

Td = 0.1s
Ad = 10%
Td = 0.1s
Ad = 20%
Td = 0.1s
Ad = 40%
Td = 1 s
Ad = 20%
Td = 1 s
Ad = 10%
Td = 1 s
Ad = 5%

Na ECa-m (%) Na ECa-m (%) Na ECa-m
(%)
Na ECa-m (%) Na ECa-m (%) Na ECa-m (%)
1 164 162 178 9.88 175 8.03 151 6.79 156 3.7 166 2.47 182 12.35

2 174 177 194 9.61 190 7.35 164 7.35 169 4.52 182 2.83 199 12.43

3 171 173 191 10.41 185 6.94 161 6.94 165 4.62 178 2.89 194 12.14

4 199 197 217 10.15 212 7.61 182 7.61 188 4.57 204 3.55 223 13.20

5 134 132 145 9.85 142 7.58 121 8.33 126 4.55 135 2.27 147 11.36

6 227 224 247 10.27 240 7.14 207 7.59 214 4.46 232 3.57 255 13.84

Nr - number; Nh - number of incidents counted from hearing in real time;

Nm - number of incidents counted manually the software MES Cough Analyser;

Na - number of incidents automatically counted by cough analyser;

ECa-m - counting error; Td - discrimination time; Ad - amplitude of discrimination.

ECa-m was assessed according to the following mathematical formula:

graphic file with name 1475-925X-9-17-i2.gif

Nm - number of incidents counted manually by the software MES Cough Analyser

Na - number of incidents automatically counted by the cough analyser

The results of the calibration tests showed that the optimal parameters of automatic analysis are time discrimination = 1 second and amplitude discrimination = 10%. This means that the recognition of a signal begins if the amplitude reaches 10% as well as disappearing at the level of 10%.

Using these parameters of automatic analysis means that ECa-m was equal to 2.93% (range 2.27-3.57), thus ECa-m was < 5%.

Third - automatic counting verified against that achieved via manual counting by the software MES Cough Analyser during prolonged monitoring (Table 3).

Table 3.

The validation of the automatic measurement of cough against manual analysis by the MES Cough Analyser.

Nr T
[h]
Na Nm TP FN FP FP rate TN SENS
[%]
SPEC
[%]
AGREE
[%]
1 8 1282 1238 1198 40 84 0.0035 23672 96.8 99.6 99.5

2 8 1343 1302 1277 25 66 0.0026 25285 98.1 99.7 99.6

3 8 1154 1120 1105 15 49 0.0019 25552 98.7 99.8 99.7

4 8 1705 1648 1620 28 85 0.0036 23692 98.3 99.6 99.5

5 8 1587 1543 1498 45 89 0.0035 25147 97.1 99.6 99.5

6 8 1782 1715 1657 58 125 0.0053 23680 96.6 99.5 99.3

7 16 2184 2114 2048 66 136 0.0027 50722 96.9 99.7 99.6

8 16 2730 2648 2573 75 157 0.0030 51725 97.2 99.7 99.6

9 16 3155 3041 2921 120 234 0.0045 51279 96.0 99.5 99.3

10 16 3286 3159 3024 135 262 0.0053 48928 95.7 99.5 99.2

11 20 3426 3308 3168 140 258 0.0041 62033 95.7 99.6 99.4

12 20 4311 4162 3976 186 335 0.0054 60805 95.5 99.5 99.2

13 20 4139 3984 3850 134 289 0.0046 61451 96.6 99.5 99.3

Nr - number of measurement period; T - duration of measurement in hours; Nm - number of incidents counted manually by software for the MES Cough Analyser; Na - number of incidents automatically counted by cough analyser; TP - true positives = number of incidents detected by automatic counting and confirmed by manual analysis; FN - false negatives = number of incidents detected only by manual analysis (not by automatic counting); FP - false positives = number of incidents detected only by automatic analysis (not by manual counting); TN - true negatives = number of potential incidents not registered by automatic or manual counting (as the discrimination time was 1 second, a TN was counted as seconds of measurement without incidents registered either by automatic or manual analysis);

graphic file with name 1475-925X-9-17-i3.gif

The thirteen measurements in healthy volunteers lasted a total of 172 hours.

The parameters of digital measurement accepted for signal detection were based on the results of the previous step of calibration: discrimination time = 1 second; minimal amplitude of incident = 10%. Thus, the software enabled registration of a 1-second incident as a cough (minimal cough duration = 1 second). A 1-second interval was required to discriminate between incidents. The software presented each incident as a percentage of the maximum amplitude achieved by an individual patient. The recognition of a signal began if the amplitude reached 10% and also disappeared at the level of 10%.

The results of the validation process enabled the calculation of sensitivity greater than 95% (median = 96.8; range 95.5-98.7), a specificity greater than 99% (median = 99.6; range 99.5-99.8), and a median false positive rate = 0.0036 (range 0.0019-0.0054) (Table 3).

Time was measured by the use of a quartz generator with a frequency of 3.62 MHz and an accuracy and stability of +/-50 ppm. Thus accuracy of the time measurement is very high, at the level of one-tenth of a millisecond. The filters of frequency used by us guaranteed the time of response < 0.01 second.

The hardware for the CA allows for a 0.1-second resolution time in registering signals. Thus, the hypothetical error related to the time measurement should be extremely low and acceptable.

Clinical experiment

To eliminate sounds of other than cough origin (i.e. extraneous noise) during the clinical part, we withdrew signals with an amplitude lower than 50% of the maximum amplitude obtained during cough. We quantified cough in terms of the number of incidents and the time spent coughing in seconds per hour; we analysed day and night periods separately.

Subjective measures of cough

Patients were asked to self-assess their cough simultaneously with the CA monitoring. The evaluation included the intensity and duration of the symptom based on a Numerical Rating Scale (NRS: 1 = no cough to 10 = worst cough) and a cough scoring system recommended by the ERS [4,6].

Statistical analysis

The validation of the CA revealed a sensitivity for discriminating between coughs equal to 95%. Based on clinical experience, we had assumed the sensitivity of the cough score to be 55%. We calculated that to obtain a power of 70% (p = 0.05) for the study we would need a sample size involving 16 patients [12].

The time for monitoring was arbitrarily divided into night (N) and day (D) (from 22.00 to 6.00 and the time remaining, respectively). The steps for the calculation included: (1) counting the number of cough incidents during D and N separately; and (2) calculating the mean number of incidents per hour for D and N. These mean values were subsequently used for further analysis of correlations between particular features. The same was calculated for time spent coughing. Statistical analysis was conducted using a licensed version of statistical software: STATISTICA PL 5.0 for Windows. The distribution of variables using the Shapiro-Wilk test was abnormal, therefore non-parametric statistical tests were chosen. A Wilcoxon rank test was performed to assess the differences between particular parameters. Spearman correlations were used to examine the relationship between subjective and objective measures of cough.

Results

Sixteen patients with chronic cough were included in the CA assessment (11 females; median age 49.5 years [range 19-58]) (Table 1). Among these patients, three did not finish the subjective assessment. Thus a statistical assessment of the correlation between the objective and subjective cough evaluations was conducted for 13 patients (Table 4).

Table 4.

Objective and subjective parameters of cough

Nr Study duration
(h)
Time spent coughing per hour Number of incidents per hour Longest interval between incidents (min) Cough scoring NRS
1-10


Total
(sec)
Day
(sec)
Night
(sec)
Total Day Night Day Night
1 24 17 12 27 63 31 128 85 5 4 7

2 24 47 67 7 51 70 13 88 4 3 4

3 17.5 20 30 9 56 72 38 277 - - -

4 24 40 16 89 61 21 142 112 3 0 4

5 24 12 15 7 37 44 25 168 4 2 6

6 22.5 1 1 0 2 3 0 622 1 0 3

7 20 18 28 4 40 59 11 95 3 1 4

8 20.5 5 9 0 13 22 1 284 4 3 5

9 24 34 51 2 71 104 4 153 5 3 9

10 21.5 49 75 4 105 160 12 117 - - -

11 15 52 78 29 113 194 41 60 - - -

12 22 8 12 2 16 22 5 129 0 2 1

13 19 15 24 2 29 47 4 101 3 2 7

14 23.5 4 7 0 3 4 0 601 3 2 5

15 17 0 0 0 0 0 0 - 0 0 1

16 20 16 26 1 33 53 2 95 3 0 8

Cough scoring recommended by the ERS [6]. Cough scoring during daytime: 0 = no cough during the day; 1 = cough for one short period; 2 = cough for more than two short periods; 3 = frequent coughing, which did not interfere with usual daytime activities; 4 = frequent coughing, which did interfere with usual daytime activities; 5 = distressing coughs most of the day. Cough scoring during night-time: 0 = no cough during the night; 1 = cough on waking only; 2 = waking once or early due to cough; 3 = frequent waking due to cough activities; 4 = frequent coughs most of the night; 5 = distressing coughs preventing any sleep.

Compatibility

The CA was easy to use and highly acceptable to the patients, apart from two (patients 12 and 13) who removed it early due to discomfort during the night. Eight other patients decided for themselves to shorten the time of monitoring due to occupational obligations.

Analysis of objective cough monitoring

Among the 16 patients included in the analysis, the median duration time of objective cough monitoring (the entire study period) was 21 hours and 45 minutes (range 15-24 hours) (Table 4). The median of cough incidents for the whole study period was 38.5 per hour, with a wide range of 0-113. The number of incidents was higher during the day than the night-time period. The median number of incidents per hour during the day was 45.5 (range 0-194); at night this was 8 (range 0-142; p = 0.04, Wilcoxon rank test). Despite the lack of a significant relation between the number of cough events per hour during D and N (r = 0.47; p = 0.063), there was a moderate correlation between the number of all cough incidents during D and N (r = 0.53; p = 0.034): patients who coughed more during the day also coughed more at night (Table 5).

Table 5.

Correlation between different parameters of cough

Spearman correlation

Number of coughs per hour Time spent coughing per hour (sec/h) Cough score for a night period

Total Day Night Total Day Night
Number of incidents per hour during daytime 0.47 (p = 0.064)

Time spent coughing per hour (sec/h) during daytime 0.60 (p = 0.014)

Cough intensity by the NRS 0.52 (p = 0.066) 0.37 (p = 0.21)

Cough score for a day period 0.60 (p = 0.029) 0.48 (p = 0.1) 0.77 (p = 0.002)

Cough score for a night period 0.29 (p = 0.34) 0.26 (p = 0.4)

The median time spent coughing for the study group was 16.5 seconds per hour with a wide range between patients (0-52). Time spent coughing was higher during the day than at night. The median time spent coughing during the day was 20 seconds per hour (range 0-78), whereas at night this was 3 seconds per hour (range 0-89; p = 0.02, Wilcoxon rank test). There was a moderate correlation between time spent coughing per hour during D and N (r = 0.60; p = 0.015).

Analysis of subjective measurement

Thirteen patients completed the subjective evaluation form (Table 4). The median cough score during the day was 3 (range 0-5) and was higher than at night (median 2, range 0-4; p = 0.02; Wilcoxon rank test). There was a moderate correlation between cough scoring for D and N (r = 0.77; p = 0.002). Patients with a high cough score for the day tended to assess night coughing similarly (Table 5).

Correlation between subjective and objective measures

For the daytime, subjective cough scoring correlated moderately with the number of all cough incidents (r = 0.63; p = 0.022) and the number of cough incidents per hour (r = 0.60; p = 0.029) (Table 5 and Figure 2). However, for the daytime period there was no significant correlation between cough score and the time spent coughing per hour (r = 0.48; p = 0.1). As assessed for the night-time period, there was no significant correlation between subjective cough scoring and all studied objective parameters, such as the number of incidents per hour (r = 0.29; p = 0.34) (Figure 3) or time spent coughing per hour (r = 0.26; p = 0.4). There was no significant correlation between the NRS and either cough incidents per hour (r = 0.52; p = 0.066) or time spent coughing per hour (r = 0.37; p = 0.21).

Figure 2.

Figure 2

Correlation between subjective cough scoring and the number of cough incidents per hour assessed for one daytime period (r = 0.60; p = 0.029).

Figure 3.

Figure 3

Correlation between subjective cough scoring and the number of cough incidents per hour assessed for one night-time period (r = 0.29; p = 0.34).

Discussion

In the pre-clinical assessment our new portable automatic cough analyser seemed to be a simple and practical but accurate and reliable method for the objective prolonged monitoring of cough in an ambulatory setting. Our pilot clinical study compared subjective and objective evaluations of cough in patients with chronic cough. The results showed a moderate correlation between cough scoring and the number of cough incidents measured with the CA during the day, whereas there was a lack of correlation between these parameters at night.

Until now the relationships between different subjective and objective measures of cough have not been clarified and have been controversial in different trials [9-11]. In children with recurrent cough, 24-hour cough counts correlated moderately with cough scores assessed through the use of a colour-coded chart and a Visual Analogue Scale [7]. When the observation period was divided into day- and night-time, subjective night-time reporting of cough by children was unreliable [13-17]. Therefore, some authors have suggested that night-time cough should be removed from children's symptom diaries [16,18]. In adult patients with chronic obstructive pulmonary disease, subjective measures of cough correlate moderately with time spent coughing both during the day and at night [19]. By contrast, in patients with asthma or chronic dry cough subjective reporting correlates with cough counts only in patients with chronic dry cough and only during the day [6]. In the present study, we demonstrate a moderate correlation between subjective cough scoring and the number of cough incidents per hour measured with a CA for the daytime. However, no such correlation was found for the night-time period. Thus, despite the main limitation of our study due to the small sample size, our results support the observation that nocturnal cough might be unreliably reported in adults. An explanation for this phenomenon is difficult. Cough has been shown to be significantly influenced by the psychological status of the subjects [20,21]. We might hypothesize that the negative impact on quality of life from night cough is significant and leads to an overestimation of its severity. The other possible explanation is that patients transfer their daytime evaluation to the night-time assessment. Moreover, they might poorly and subjectively rate cough as a symptom both by day and night.

Recently, the need for integrated recording systems for cough assessment has been stressed, particularly in the clinical evaluation of drug efficacy [4,5]. There is still a need to differentiate between cough and non-cough sound [13,22-25]. In our study, the localization of the low-volume unidirectional contact microphone helped to eliminate extraneous noise and increase the chance that only high-amplitude sounds occurring close to the microphone would be detected. Our pilot study is an attempt to find the optimal means of reliable chronic cough assessment by using a practical and simple method.

It is worth mentioning that a group from Leicester, UK, introduced an automated system for the 24-hour monitoring of cough frequency. Their studies have proved to be significant, with repeatable differences seen in cough frequency between patients with chronic cough and healthy controls [26]; they have further validated their system against manual counts obtained by a trained observer [27]. Thus, they confirm that the automated counting of cough events is a reliable and objective method.

However, it is likely that automated cough monitoring is both device and method specific; therefore, the findings of previous studies cannot be extrapolated to new devices.

The unsatisfactory effectiveness of currently available antitussives, particularly in patients with advanced lung disease, has provoked increased interest in the development of some novel approaches. One of these is to reach opioid receptors in the trachea-bronchial tract using nebulised opioids [28] or other targets involved in cough, including transient receptor potential vanilloid-1 antagonists, selective cannabinoid agonists, maxi-K channel openers and purinergic receptor antagonists [for a review of this see [29]].

Clinical trials on new antitussive drugs would require the thorough objective assessment of the intensity and frequency of cough, which means that introducing portable devices such as a CA might be of clinical relevance.

Conclusions

We conclude that appropriate night-time cough evaluation requires both subjective and objective monitoring. The severity of cough defined by a patient may not represent its frequency and duration when measured objectively. The use of ambulatory cough analysers should not be limited to research but might be helpful in clinical practice, particularly when symptomatic treatment is the main or only purpose of the approach.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

MK and IDK were involved in the design of the study protocol, in the patients enrolment and examination, in the analysis and interpretation of data and writing the paper. IDK performed a statistical analysis. LG took a part in the patients enrolment to the study, in a data collection and analysis, and revised the manuscript critically. EJ made substantial contribution to conception and design of the study protocol, analysis and interpretation of data, coordination of the trial and helped to draft the manuscript. All authors read and approved the final manuscript.

Contributor Information

Malgorzata Krajnik, Email: malgorzata.krajnik@wp.pl.

Iwona Damps-Konstanska, Email: damik@amg.gda.pl.

Lucyna Gorska, Email: lucynagorska@amg.gda.pl.

Ewa Jassem, Email: ejassem@amg.gda.pl.

References

  1. Andre E, Gatti R, Trevisani M, Preti D, Baraldi PG, Patacchini R, Geppetti P. Transient receptor potential ankyrin receptor 1 is a novel target for pro-tussive agents. Br J Pharmacol. 2009;158:1621–1628. doi: 10.1111/j.1476-5381.2009.00438.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Kamei J, Yoshikawa Y, Saitoh A. Effect of N-arachidonoyl-(2-methyl-4-hydroxyphenyl) amine (VDM11), an anandamine transporter inhibitor, on capsaicin-induced cough in mice. Cough. 2006;2:2. doi: 10.1186/1745-9974-2-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Dicpinigaitis PV. Potential future therapies for the management of cough: ACCP evidence-based clinical practice guidelines. Chest. 2006;129:284–286. doi: 10.1378/chest.129.1_suppl.284S. [DOI] [PubMed] [Google Scholar]
  4. Morice AH, Fontana GA, Belvisi MG, Birring SS, Chung KF, Dicpinigaitis PV, Kastelik JA, McGarvey LP, Smith JA, Tatar M, Widdicombe J. ERS Task Force. ERS guidelines on the assessment of cough. Eur Respir J. 2007;29:1256–1276. doi: 10.1183/09031936.00101006. [DOI] [PubMed] [Google Scholar]
  5. Irwin RS. Assessing cough severity and efficacy of therapy in clinical research. Chest. 2006;129:232S–237S. doi: 10.1378/chest.129.1_suppl.232S. [DOI] [PubMed] [Google Scholar]
  6. Hsu JY, Stone RA, Logan-Sinclair RB, Worsdell M, Busst CM, Chung KF. Coughing frequency in patients with persistent cough: assessment using a 24 hour ambulatory recorder. Eur Respir J. 1994;7:1246–1253. doi: 10.1183/09031936.94.07071246. [DOI] [PubMed] [Google Scholar]
  7. Chang AB, Phelan PD, Robertson CF, Roberts RG, Sawyer SM. Relation between measurements of cough severity. Arch Dis Child. 2003;88:57–60. doi: 10.1136/adc.88.1.57. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Li AM, Tsang TWT, Chan DFY, Lam HS, So HK, Sung RY, Fok TF. Cough frequency in children with mild asthma correlated with sputum neutrophil count. Thorax. 2006;61:747–750. doi: 10.1136/thx.2005.050815. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Decalmer S, Webster D, Kelsall A, McGuinness K, Woodcock A, Smith J. Chronic cough: how do cough reflex sensitivity and subjective assessments correlate with objective cough counts during ambulatory monitoring? Thorax. 2007;62:329–334. doi: 10.1136/thx.2006.067413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Kelsall A, Decalmer S, Webster D, Brown N, McGuinness K, Woodcock A, Smith J. How to quantify coughing: correlations with quality of life in chronic cough. Eur Respir J. 2008;32:175–179. doi: 10.1183/09031936.00101307. [DOI] [PubMed] [Google Scholar]
  11. Birring SS, Fleming T, Matos S, Raj AA, Evans DH, Pavord ID. The Leicester Cough Monitor: preliminary validation of an automated cough detection system in chronic cough. Eur Respir J. 2008;31:1013–1018. doi: 10.1183/09031936.00057407. [DOI] [PubMed] [Google Scholar]
  12. Altman DG. In: Statistics in practice. Gore SM, Altman DG, editor. London, UK; British Medical Association; 1982. How large a sample? [Google Scholar]
  13. Matos S, Birring SS, Pavord ID, Evans DH. Detection of cough signals in continuous audio recordings using hidden Markov models. IEEE Trans Biomed Eng. 2006;53:1078–1083. doi: 10.1109/TBME.2006.873548. [DOI] [PubMed] [Google Scholar]
  14. Falconer A, Oldman C, Helms P. Poor agreement between reported and recorded nocturnal cough in asthma. Pediatr Pulmonol. 1993;15:209–211. doi: 10.1002/ppul.1950150405. [DOI] [PubMed] [Google Scholar]
  15. Archer LNJ, Simpson H. Night cough counts and diary card scores in asthma. Arch Dis Child. 1985;60:473–474. doi: 10.1136/adc.60.5.473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Chang AB, Newman RG, Carlin JB, Phelan PD, Robertson CF. Subjective scoring of cough in children: parent-completed vs child-completed diary cards vs an objective method. Eur Respir J. 1998;11:462–466. doi: 10.1183/09031936.98.11020462. [DOI] [PubMed] [Google Scholar]
  17. Hamutcu R, Francis J, Karakoc F, Bush A. Objective monitoring of cough in children with cystic fibrosis. Pediatr Pulmonol. 2002;34:331–335. doi: 10.1002/ppul.10174. [DOI] [PubMed] [Google Scholar]
  18. McKenzie S. In: Childhood asthma and other wheezing disorders. Silverman M, editor. London: Chapman & Hall Medical; 1995. Clinical features and their assessment; pp. 175–200. [Google Scholar]
  19. Smith J, Owen E, Earis J, Woodcock A. Cough in COPD: correlation of objective monitoring with cough challenge and subjective assessments. Chest. 2006;130:379–385. doi: 10.1378/chest.130.2.379. [DOI] [PubMed] [Google Scholar]
  20. Dales RE, Spitzer WO, Schechter MT, Suissa S. The influence of psychological status on respiratory symptom reporting. Am Rev Respir Dis. 1989;139:1459–1463. doi: 10.1164/ajrccm/139.6.1459. [DOI] [PubMed] [Google Scholar]
  21. Rietveld S, Van Beest I, Everaerd W. Psychological confounds in medical research: the example of excessive cough in asthma. Behav Res Ther. 2000;38:791–800. doi: 10.1016/S0005-7967(99)00099-6. [DOI] [PubMed] [Google Scholar]
  22. Coyle MA, Keenan DB, Henderson LS, Watkins ML, Haumann BK, Mayleben DW, Wilson MG. Evaluation of an ambulatory system for the quantification of cough frequency in patients with chronic obstructive pulmonary disease. Cough. 2005;1:3. doi: 10.1186/1745-9974-1-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Murata A, Ohota N, Shibuya A, Ono H, Kudoh S. New non-invasive automatic cough counting program based on 6 types of classified cough sounds. Intern Med. 2006;45:391–397. doi: 10.2169/internalmedicine.45.1449. [DOI] [PubMed] [Google Scholar]
  24. Barry SJ, Dane AD, Morice AH, Walmsley AD. The automatic recognition and counting of cough. Cough. 2006;2:8. doi: 10.1186/1745-9974-2-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Smith J. Ambulatory methods for recording cough. Pulm Pharmacol Ther. 2007;20:313–318. doi: 10.1016/j.pupt.2006.10.016. [DOI] [PubMed] [Google Scholar]
  26. Birring SS, Matos S, Patel RB, Prudon B, Evans DH, Pavord ID. Cough frequency, cough sensitivity and health status in patients with chronic cough. Respir Med. 2006;100:1105–1109. doi: 10.1016/j.rmed.2005.09.023. [DOI] [PubMed] [Google Scholar]
  27. Matos S, Birring SS, Pavord ID, Evans DH. An automated system for 24-h monitoring of cough frequency: the leicester cough monitor. IEEE Trans Biomed Eng. 2007;54:1472–1479. doi: 10.1109/TBME.2007.900811. [DOI] [PubMed] [Google Scholar]
  28. Krajnik M, Podolec Z, Siekierka M, Sykutera M, Pufal E, Sobanski P, Makarewicz R, Neef C, Punt N, Zylicz Z. Morphine inhalation in cancer patients. A comparison of different nebulization techniques using pharmacokinetic, spirometric and gasometric parameters. J Pain Symptom Manage. 2009. [DOI] [PubMed]
  29. Barnes PJ. The problem of cough and development of new antitussives. Pulm Pharmacol Ther. 2007;20:416–422. doi: 10.1016/j.pupt.2006.11.001. [DOI] [PubMed] [Google Scholar]

Articles from BioMedical Engineering OnLine are provided here courtesy of BMC

RESOURCES